(CLDT) Chatham Lodging Trust REIT - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US16208T1025
Stock: Hotels, Suites, Extended-Stay, Select-Service, Upscale
Total Rating 26
Risk 34
Buy Signal 0.29
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 5.21% |
| Yield on Cost 5y | 3.37% |
| Yield CAGR 5y | 72.61% |
| Payout Consistency | 82.5% |
| Payout Ratio | 4.0% |
| Risk 5d forecast | |
|---|---|
| Volatility | 28.3% |
| Relative Tail Risk | -10.1% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.33 |
| Alpha | -23.82 |
| Character TTM | |
|---|---|
| Beta | 0.990 |
| Beta Downside | 1.033 |
| Drawdowns 3y | |
|---|---|
| Max DD | 51.60% |
| CAGR/Max DD | -0.27 |
Description: CLDT Chatham Lodging Trust REIT December 29, 2025
Chatham Lodging Trust (CLDT) is a self-advised REIT that concentrates on upscale extended-stay and premium-branded select-service hotels, currently owning 34 properties with 5,166 rooms across 15 states and D.C.
As of Q3 2024, CLDT reported an occupancy rate of roughly 71% and a RevPAR of $84, while its debt-to-EBITDA leverage sits near 4.5×, reflecting a moderate balance-sheet risk. The extended-stay segment benefits from sustained remote-work trends and a slower-recovering corporate travel market, whereas select-service demand is being buoyed by higher discretionary spending as inflation eases.
If you want a more granular financial breakdown, checking ValueRay’s CLDT analysis could be a useful next step.
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income: 8.73m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -2.24 > 1.0 |
| NWC/Revenue: -4.20% < 20% (prev -2.20%; Δ -2.00% < -1%) |
| CFO/TA 0.05 > 3% & CFO 64.8m > Net Income 8.73m |
| Net Debt (345.8m) to EBITDA (88.0m): 3.93 < 3 |
| Current Ratio: 0.67 > 1.5 & < 3 |
| Outstanding Shares: last quarter (49.6m) vs 12m ago 1.09% < -2% |
| Gross Margin: 34.66% > 18% (prev 0.35%; Δ 3431 % > 0.5%) |
| Asset Turnover: 24.42% > 50% (prev 24.28%; Δ 0.14% > 0%) |
| Interest Coverage Ratio: 1.06 > 6 (EBITDA TTM 88.0m / Interest Expense TTM 26.0m) |
Altman Z'' -1.53
| A: -0.01 (Total Current Assets 25.3m - Total Current Liabilities 38.0m) / Total Assets 1.18b |
| B: -0.25 (Retained Earnings -297.9m / Total Assets 1.18b) |
| C: 0.02 (EBIT TTM 27.6m / Avg Total Assets 1.24b) |
| D: -0.75 (Book Value of Equity -297.4m / Total Liabilities 397.1m) |
| Altman-Z'' Score: -1.53 = D |
Beneish M -3.15
| DSRI: 0.93 (Receivables 3.91m/4.36m, Revenue 302.4m/314.4m) |
| GMI: 1.01 (GM 34.66% / 34.88%) |
| AQI: 1.00 (AQ_t 0.96 / AQ_t-1 0.96) |
| SGI: 0.96 (Revenue 302.4m / 314.4m) |
| TATA: -0.05 (NI 8.73m - CFO 64.8m) / TA 1.18b) |
| Beneish M-Score: -3.15 (Cap -4..+1) = AA |
What is the price of CLDT shares?
As of February 08, 2026, the stock is trading at USD 7.57 with a total of 254,125 shares traded.
Over the past week, the price has changed by +6.47%, over one month by +8.92%, over three months by +19.28% and over the past year by -9.95%.
Over the past week, the price has changed by +6.47%, over one month by +8.92%, over three months by +19.28% and over the past year by -9.95%.
Is CLDT a buy, sell or hold?
Chatham Lodging Trust REIT has received a consensus analysts rating of 4.00.
Therefore, it is recommended to buy CLDT.
- StrongBuy: 2
- Buy: 0
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CLDT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 8 | 5.7% |
| Analysts Target Price | 8 | 5.7% |
| ValueRay Target Price | 8 | 6.1% |
CLDT Fundamental Data Overview February 03, 2026
P/E Trailing = 711.0
P/E Forward = 238.0952
P/S = 1.1963
P/B = 0.4584
P/EG = 3.13
Revenue TTM = 302.4m USD
EBIT TTM = 27.6m USD
EBITDA TTM = 88.0m USD
Long Term Debt = 338.8m USD (from longTermDebt, last quarter)
Short Term Debt = 110.0m USD (from shortTermDebt, last fiscal year)
Debt = 359.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 345.8m USD (from netDebt column, last quarter)
Enterprise Value = 706.4m USD (360.5m + Debt 359.1m - CCE 13.2m)
Interest Coverage Ratio = 1.06 (Ebit TTM 27.6m / Interest Expense TTM 26.0m)
EV/FCF = 12.75x (Enterprise Value 706.4m / FCF TTM 55.4m)
FCF Yield = 7.85% (FCF TTM 55.4m / Enterprise Value 706.4m)
FCF Margin = 18.32% (FCF TTM 55.4m / Revenue TTM 302.4m)
Net Margin = 2.89% (Net Income TTM 8.73m / Revenue TTM 302.4m)
Gross Margin = 34.66% ((Revenue TTM 302.4m - Cost of Revenue TTM 197.6m) / Revenue TTM)
Gross Margin QoQ = 36.68% (prev 38.47%)
Tobins Q-Ratio = 0.60 (Enterprise Value 706.4m / Total Assets 1.18b)
Interest Expense / Debt = 1.64% (Interest Expense 5.90m / Debt 359.1m)
Taxrate = 0.0% (0.0 / 3.59m)
NOPAT = 27.6m (EBIT 27.6m * (1 - 0.00%))
Current Ratio = 0.67 (Total Current Assets 25.3m / Total Current Liabilities 38.0m)
Debt / Equity = 0.48 (Debt 359.1m / totalStockholderEquity, last quarter 749.4m)
Debt / EBITDA = 3.93 (Net Debt 345.8m / EBITDA 88.0m)
Debt / FCF = 6.24 (Net Debt 345.8m / FCF TTM 55.4m)
Total Stockholder Equity = 754.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 0.71% (Net Income 8.73m / Total Assets 1.18b)
RoE = 1.16% (Net Income TTM 8.73m / Total Stockholder Equity 754.1m)
RoCE = 2.53% (EBIT 27.6m / Capital Employed (Equity 754.1m + L.T.Debt 338.8m))
RoIC = 2.46% (NOPAT 27.6m / Invested Capital 1.12b)
WACC = 5.61% (E(360.5m)/V(719.6m) * Re(9.56%) + D(359.1m)/V(719.6m) * Rd(1.64%) * (1-Tc(0.0)))
Discount Rate = 9.56% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.76%
[DCF Debug] Terminal Value 87.22% ; FCFF base≈69.2m ; Y1≈76.0m ; Y5≈97.1m
Fair Price DCF = 51.94 (EV 2.87b - Net Debt 345.8m = Equity 2.52b / Shares 48.5m; r=5.90% [WACC]; 5y FCF grow 11.30% → 2.90% )
EPS Correlation: 4.65 | EPS CAGR: 130.5% | SUE: 4.0 | # QB: 1
Revenue Correlation: 40.63 | Revenue CAGR: 8.88% | SUE: -1.07 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.19 | Chg30d=-0.120 | Revisions Net=+0 | Analysts=1
EPS next Year (2026-12-31): EPS=-0.14 | Chg30d=-0.090 | Revisions Net=+0 | Growth EPS=-180.0% | Growth Revenue=-0.3%
P/E Forward = 238.0952
P/S = 1.1963
P/B = 0.4584
P/EG = 3.13
Revenue TTM = 302.4m USD
EBIT TTM = 27.6m USD
EBITDA TTM = 88.0m USD
Long Term Debt = 338.8m USD (from longTermDebt, last quarter)
Short Term Debt = 110.0m USD (from shortTermDebt, last fiscal year)
Debt = 359.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 345.8m USD (from netDebt column, last quarter)
Enterprise Value = 706.4m USD (360.5m + Debt 359.1m - CCE 13.2m)
Interest Coverage Ratio = 1.06 (Ebit TTM 27.6m / Interest Expense TTM 26.0m)
EV/FCF = 12.75x (Enterprise Value 706.4m / FCF TTM 55.4m)
FCF Yield = 7.85% (FCF TTM 55.4m / Enterprise Value 706.4m)
FCF Margin = 18.32% (FCF TTM 55.4m / Revenue TTM 302.4m)
Net Margin = 2.89% (Net Income TTM 8.73m / Revenue TTM 302.4m)
Gross Margin = 34.66% ((Revenue TTM 302.4m - Cost of Revenue TTM 197.6m) / Revenue TTM)
Gross Margin QoQ = 36.68% (prev 38.47%)
Tobins Q-Ratio = 0.60 (Enterprise Value 706.4m / Total Assets 1.18b)
Interest Expense / Debt = 1.64% (Interest Expense 5.90m / Debt 359.1m)
Taxrate = 0.0% (0.0 / 3.59m)
NOPAT = 27.6m (EBIT 27.6m * (1 - 0.00%))
Current Ratio = 0.67 (Total Current Assets 25.3m / Total Current Liabilities 38.0m)
Debt / Equity = 0.48 (Debt 359.1m / totalStockholderEquity, last quarter 749.4m)
Debt / EBITDA = 3.93 (Net Debt 345.8m / EBITDA 88.0m)
Debt / FCF = 6.24 (Net Debt 345.8m / FCF TTM 55.4m)
Total Stockholder Equity = 754.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 0.71% (Net Income 8.73m / Total Assets 1.18b)
RoE = 1.16% (Net Income TTM 8.73m / Total Stockholder Equity 754.1m)
RoCE = 2.53% (EBIT 27.6m / Capital Employed (Equity 754.1m + L.T.Debt 338.8m))
RoIC = 2.46% (NOPAT 27.6m / Invested Capital 1.12b)
WACC = 5.61% (E(360.5m)/V(719.6m) * Re(9.56%) + D(359.1m)/V(719.6m) * Rd(1.64%) * (1-Tc(0.0)))
Discount Rate = 9.56% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.76%
[DCF Debug] Terminal Value 87.22% ; FCFF base≈69.2m ; Y1≈76.0m ; Y5≈97.1m
Fair Price DCF = 51.94 (EV 2.87b - Net Debt 345.8m = Equity 2.52b / Shares 48.5m; r=5.90% [WACC]; 5y FCF grow 11.30% → 2.90% )
EPS Correlation: 4.65 | EPS CAGR: 130.5% | SUE: 4.0 | # QB: 1
Revenue Correlation: 40.63 | Revenue CAGR: 8.88% | SUE: -1.07 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.19 | Chg30d=-0.120 | Revisions Net=+0 | Analysts=1
EPS next Year (2026-12-31): EPS=-0.14 | Chg30d=-0.090 | Revisions Net=+0 | Growth EPS=-180.0% | Growth Revenue=-0.3%